ASH 2017 | The DUO trial: providing new hope for CLL patients
Stephan Stilgenbauer, MD, PhD, of the University of Ulm, Ulm, Germany, talks about the results of the DUO trial, a randomized analysis of ofatumumab versus duvelisib in relapsed refractory CLL patients. Trial was run over a couple of years and met it’s primary endpoint of progression-free survival superiority of duvelisib over ofatumumab. This will likely lead to licensing of duvelisib as a novel treatment option for CLL patients, which will provide new hope beyond chemoimmunotherapy.
Recorded at the American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.
Get great new content delivered to your inboxSign up